ROIVANT SCIENCES LTD (ROIV) Stock Fundamental Analysis

NASDAQ:ROIV • BMG762791017

27.52 USD
+0.04 (+0.15%)
At close: Feb 19, 2026
27.52 USD
0 (0%)
After Hours: 2/19/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall ROIV gets a fundamental rating of 4 out of 10. We evaluated ROIV against 521 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ROIV as it has an excellent financial health rating, but there are worries on the profitability. ROIV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year ROIV has reported negative net income.
  • In the past year ROIV has reported a negative cash flow from operations.
  • In the past 5 years ROIV reported 4 times negative net income.
  • ROIV had a negative operating cash flow in each of the past 5 years.
ROIV Yearly Net Income VS EBIT VS OCF VS FCFROIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B 3B 4B

1.2 Ratios

  • ROIV's Return On Assets of -7.39% is amongst the best of the industry. ROIV outperforms 85.99% of its industry peers.
  • ROIV has a Return On Equity of -8.57%. This is amongst the best in the industry. ROIV outperforms 88.68% of its industry peers.
Industry RankSector Rank
ROA -7.39%
ROE -8.57%
ROIC N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROIV Yearly ROA, ROE, ROICROIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • Looking at the Gross Margin, with a value of 96.41%, ROIV belongs to the top of the industry, outperforming 96.74% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ROIV has remained more or less at the same level.
  • ROIV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
ROIV Yearly Profit, Operating, Gross MarginsROIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 5K 10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • ROIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ROIV has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ROIV has more shares outstanding
  • ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ROIV Yearly Shares OutstandingROIV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
ROIV Yearly Total Debt VS Total AssetsROIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • ROIV has an Altman-Z score of 17.05. This indicates that ROIV is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 17.05, ROIV belongs to the top of the industry, outperforming 87.91% of the companies in the same industry.
  • There is no outstanding debt for ROIV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.05
ROIC/WACCN/A
WACC9.25%
ROIV Yearly LT Debt VS Equity VS FCFROIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 2B 4B

2.3 Liquidity

  • A Current Ratio of 33.70 indicates that ROIV has no problem at all paying its short term obligations.
  • ROIV has a better Current ratio (33.70) than 98.27% of its industry peers.
  • ROIV has a Quick Ratio of 33.70. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
  • ROIV's Quick ratio of 33.70 is amongst the best of the industry. ROIV outperforms 98.27% of its industry peers.
Industry RankSector Rank
Current Ratio 33.7
Quick Ratio 33.7
ROIV Yearly Current Assets VS Current LiabilitesROIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for ROIV have decreased strongly by -680.00% in the last year.
  • ROIV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.19%.
  • The Revenue for ROIV have been decreasing by -15.56% on average. This is quite bad
EPS 1Y (TTM)-680%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-265.22%
Revenue 1Y (TTM)-11.19%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-84.03%

3.2 Future

  • ROIV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.15% yearly.
  • Based on estimates for the next years, ROIV will show a very strong growth in Revenue. The Revenue will grow by 104.98% on average per year.
EPS Next Y-413.26%
EPS Next 2Y-132.67%
EPS Next 3Y-44.09%
EPS Next 5Y58.15%
Revenue Next Year-80.14%
Revenue Next 2Y29.27%
Revenue Next 3Y119.16%
Revenue Next 5Y104.99%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ROIV Yearly Revenue VS EstimatesROIV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
ROIV Yearly EPS VS EstimatesROIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ROIV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ROIV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ROIV Price Earnings VS Forward Price EarningsROIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ROIV Per share dataROIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • ROIV's earnings are expected to decrease with -44.09% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-132.67%
EPS Next 3Y-44.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ROIV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ROIVANT SCIENCES LTD

NASDAQ:ROIV (2/19/2026, 8:00:01 PM)

After market: 27.52 0 (0%)

27.52

+0.04 (+0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)N/A
Inst Owners65.11%
Inst Owner ChangeN/A
Ins Owners3.84%
Ins Owner Change-1.85%
Market Cap19.70B
Revenue(TTM)29.05M
Net Income(TTM)-373.97M
Analysts85.56
Price Target27.26 (-0.94%)
Short Float %4.89%
Short Ratio3.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)22.89%
Min EPS beat(2)-4.36%
Max EPS beat(2)50.15%
EPS beat(4)3
Avg EPS beat(4)58.4%
Min EPS beat(4)-4.36%
Max EPS beat(4)180.12%
EPS beat(8)6
Avg EPS beat(8)50.87%
EPS beat(12)7
Avg EPS beat(12)31.34%
EPS beat(16)9
Avg EPS beat(16)18.02%
Revenue beat(2)0
Avg Revenue beat(2)-74.21%
Min Revenue beat(2)-77.83%
Max Revenue beat(2)-70.59%
Revenue beat(4)0
Avg Revenue beat(4)-64.48%
Min Revenue beat(4)-86.28%
Max Revenue beat(4)-23.24%
Revenue beat(8)2
Avg Revenue beat(8)-34.24%
Revenue beat(12)5
Avg Revenue beat(12)-18.03%
Revenue beat(16)7
Avg Revenue beat(16)-4.01%
PT rev (1m)3.16%
PT rev (3m)36.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.38%
EPS NY rev (1m)0%
EPS NY rev (3m)11.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 968.87
P/FCF N/A
P/OCF N/A
P/B 4.52
P/tB 4.52
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0.03
BVpS6.1
TBVpS6.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.39%
ROE -8.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.41%
FCFM N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 228.14%
Cap/Sales 71.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 33.7
Quick Ratio 33.7
Altman-Z 17.05
F-Score4
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)35.38%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.59%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-680%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-265.22%
EPS Next Y-413.26%
EPS Next 2Y-132.67%
EPS Next 3Y-44.09%
EPS Next 5Y58.15%
Revenue 1Y (TTM)-11.19%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-84.03%
Revenue Next Year-80.14%
Revenue Next 2Y29.27%
Revenue Next 3Y119.16%
Revenue Next 5Y104.99%
EBIT growth 1Y-3.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.51%
EBIT Next 3Y-0.33%
EBIT Next 5YN/A
FCF growth 1Y7.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.22%
OCF growth 3YN/A
OCF growth 5YN/A

ROIVANT SCIENCES LTD / ROIV FAQ

What is the ChartMill fundamental rating of ROIVANT SCIENCES LTD (ROIV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ROIV.


What is the valuation status for ROIV stock?

ChartMill assigns a valuation rating of 0 / 10 to ROIVANT SCIENCES LTD (ROIV). This can be considered as Overvalued.


How profitable is ROIVANT SCIENCES LTD (ROIV) stock?

ROIVANT SCIENCES LTD (ROIV) has a profitability rating of 3 / 10.


What is the earnings growth outlook for ROIVANT SCIENCES LTD?

The Earnings per Share (EPS) of ROIVANT SCIENCES LTD (ROIV) is expected to decline by -413.26% in the next year.